Gene therapy for cancer using the gone gun system
使用消失的枪系统进行癌症基因治疗
基本信息
- 批准号:09557094
- 负责人:
- 金额:$ 7.55万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:1997
- 资助国家:日本
- 起止时间:1997 至 1999
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In order to establish a gene therapy system without vectors, we checked the efficacy of gene gun for gene transduction. Although we could confirm the expression of LacZ gene in pancreatic cancer cells, the transduction efficacy was very low. It is important to choose the suitable gene which can express the efficient anti-tumor effect with low concentration for gene gun System. As an anti-tumor agent, Interleukin-12 has been revealed to be a key regulator of the immune response, particularly that involving CTL and NK cells. We report herein the anti-angiogenesis effect of IL-12 on human as well as murine tumors in NK-depleted SCID mice using fibroblasts genetically engineered to secrete this cytokine. Although the in vitro growth of tumor cells was not affected by the presence of IL-12, co-inoculation of IL-12 secreting fibroblasts strongly inhibited tumor growth in immunodeficient mice. The neovascularization surrounding the tumor was remarkably inhibited in the area where the IL-12 secreting fibroblasts were implanted, resulting in the suppression of tumor growth. Lectin staining in tumor sample sections also showed a significant reduction in the number of vessels. The RNA expression of IFN-γ and its inducible antiangiogenic chemokine IP-10 was stimulated in endothelial cells cultured with IL-12. It was also found that IL-12 downregulated the expression of the endothelial cell mitogens VEGF and bFGF.The anti-tumor effects of IL-12 were accompanied by interesting histological changes consisting of a high degree of keratinization and apoptosis and a decrease in the proliferation rate of human tumors and extensive necrosis in the murine ones. Therefore, IL-12 is the candidate gene for this gene gun system.
为了建立无载体的基因治疗系统,我们检查了基因枪进行基因转导的效果。虽然我们可以证实LacZ基因在胰腺癌细胞中的表达,但转导效率很低。基因枪系统的关键是选择合适的基因,使其在低浓度下就能表达高效的抗肿瘤作用。白细胞介素-12作为一种抗肿瘤剂,已被发现是免疫应答的关键调节剂,特别是涉及CTL和NK细胞的免疫应答。我们在此报告了IL-12对NK耗竭的SCID小鼠中的人以及鼠肿瘤的抗血管生成作用,使用经基因工程改造以分泌这种细胞因子的成纤维细胞。虽然肿瘤细胞的体外生长不受IL-12的存在的影响,IL-12分泌成纤维细胞的共接种强烈抑制免疫缺陷小鼠的肿瘤生长。在植入分泌IL-12的成纤维细胞的区域中,肿瘤周围的新血管形成被显著抑制,导致肿瘤生长受到抑制。肿瘤样品切片中的凝集素染色也显示血管数量显著减少。在用IL-12培养的内皮细胞中,IFN-γ及其诱导的抗血管生成趋化因子IP-10的RNA表达被刺激。IL-12可下调血管内皮细胞有丝分裂原VEGF和bFGF的表达,并可引起肿瘤细胞高度角化和凋亡,抑制肿瘤细胞增殖,抑制肿瘤细胞坏死。因此,IL-12是该基因枪系统的候选基因。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Furukawa, T., Youssef, E.M.., Yatsuoka, T., Yokoyama, T., Makino, N., Inoue, H., Fukushige, S., Hoshi, M., Hayashi. Y., Sunamura M., and Horii, A.: "Cloning and characterization of the human UDP-N-acetylglucosamine : a-1, 3-D-mannoside b-1, 4-N-acetylgluc
古川,T.,优素福,E.M.,八冈,T.,横山,T.,牧野,N.,井上,H.,福重,S.,星,M.,林。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Matsumoto G., Sunamura M., Shimamura H., Kodama T., Hashimoto W., Kobari M., Kato K., Takeda K., Yagita H., Okumura K., Hamada H., Matsuno S.: "Adjuvant immunotherapy using genetically engineered interleukin 12 secreting fibroblasts prevents recurrence af
Matsumoto G.、Sunamura M.、Shimamura H.、Kodama T.、Hashimoto W.、Kobari M.、Kato K.、Takeda K.、Yagita H.、Okumura K.、Hamada H.、Matsuno S.:“佐剂
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Matsumoto G: "Adjuvant immuretherapy using genetically engineered interleukin 12 secreting fibroblast prevent recurrence after surgical resection of established tumors ---"Surgery. 125. 257-264 (1999)
Matsumoto G:“使用基因工程白介素 12 分泌成纤维细胞的辅助免疫疗法可预防手术切除已形成肿瘤后的复发 ---”Surgery。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Lozonschi L., Sunamura M., Kobari M., Egawa S., Ding L., Matsuno S.: "Controlling tumor angiogenesis and metastasis of C26 murin colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models."Cancer Res. 59. 1252-1258 (19
Lozonschi L.、Sunamura M.、Kobari M.、Ekawa S.、Ding L.、Matsuno S.:“通过新型基质金属蛋白酶抑制剂 KB-R7785 在两种肿瘤模型中控制 C26 鼠结肠腺癌的肿瘤血管生成和转移
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yatsuoka T., Furukawa T., Abe T., Yokoyama T., Sunamura M., Kobari M., Matsuno S., Horii A.: "Genomic Analysis of the Thymine-DNA Glycosylase (TDG) Gene on 12q22-q24.1 in Human Pancreatic Ductal Adenocarcinoma."Int J Pancreatology. 25. 97-102 (1999)
Yatsuoka T.、Furukawa T.、Abe T.、Yokoyama T.、Sunamura M.、Kobari M.、Matsuno S.、Horii A.:“12q22-q24 上胸腺嘧啶 DNA 糖基化酶 (TDG) 基因的基因组分析。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUNAMURA Makoto其他文献
SUNAMURA Makoto的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUNAMURA Makoto', 18)}}的其他基金
Development of new gemcitabine that can overcome acquired gemicitabine resistancy
开发新的吉西他滨以克服获得性吉西他滨耐药性
- 批准号:
22591512 - 财政年份:2010
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Resolution of the function of cancer cells and the application for tailor-made therapy using bio-simulation analysis
利用生物模拟分析解析癌细胞的功能并应用于量身定制的治疗
- 批准号:
18390358 - 财政年份:2006
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Induction of insulin secreting cell and its application for transplantation
胰岛素分泌细胞的诱导及其在移植中的应用
- 批准号:
14370346 - 财政年份:2002
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Adjuvant gene therapy for pancreatic cancer using hybrid type liposome vector
使用混合型脂质体载体进行胰腺癌的辅助基因治疗
- 批准号:
10470251 - 财政年份:1998
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A Study of an anti-angiogenic thcropy targetting integrins expressed on angiogenesis endotherial cells
靶向血管生成内皮细胞表达的整合素的抗血管生成细胞的研究
- 批准号:
09671278 - 财政年份:1997
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Prolongation of Islet allograft by transfection of IL-12, p40 gene into Islet
通过将IL-12、p40基因转染至胰岛来延长胰岛同种异体移植物
- 批准号:
08671407 - 财政年份:1996
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Development of Organ- and Cell-specific In Vivo Genome Editing Technique as a Novel Approach for Cancer Gene Therapy
开发器官和细胞特异性体内基因组编辑技术作为癌症基因治疗的新方法
- 批准号:
23H02763 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Developmental Programming of the Liver and Kidney in Fetal Growth with or without Gene Therapy
有或没有基因治疗的胎儿生长中肝脏和肾脏的发育规划
- 批准号:
10663585 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Precision Apheresis: stem cell isolation from patients with sickle cell disease for gene therapy using high-throughput microfluidics
精密血浆分离术:使用高通量微流控技术从镰状细胞病患者中分离干细胞进行基因治疗
- 批准号:
10723247 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Defining the Potential of Gene Therapy to Correct Motor Disabilities of CTNNB1 Syndrome Using in Vivo Mouse and in Vitro Human Cell Models
利用体内小鼠和体外人类细胞模型确定基因疗法纠正 CTNNB1 综合征运动障碍的潜力
- 批准号:
10809254 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Development of retroviral replicating vector-mediated liver-expressed iron-regulating peptide hormone, hepcidine gene therapy for esophageal cancer.
开发逆转录病毒复制载体介导的肝脏表达的铁调节肽激素、食道癌的铁碱基因疗法。
- 批准号:
23K08184 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Leveraging North-South Partnerships to Advance Cell and Gene Therapy Research Training for HIV in Uganda (C>-Uganda)
利用南北伙伴关系推进乌干达艾滋病毒细胞和基因治疗研究培训(C
- 批准号:
10688330 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
FANCC mutation correction using homology-independent targeted integration for gene therapy of Fanconi Anemia group C
使用同源无关的靶向整合校正 FANCC 突变,用于范可尼贫血 C 组的基因治疗
- 批准号:
10653342 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Development of a novel cancer gene therapy targeting prostate cancer stem cell
开发针对前列腺癌干细胞的新型癌症基因疗法
- 批准号:
22K07252 - 财政年份:2022
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Gene Therapy for the Treatment of Neurofibromatosis Type I (NF1)
治疗 I 型神经纤维瘤病 (NF1) 的基因疗法
- 批准号:
10669801 - 财政年份:2022
- 资助金额:
$ 7.55万 - 项目类别:














{{item.name}}会员




